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Autism and autism spectrum disorders (ASDs) are heterogeneous, severe neuro-
developmental disorders with core symptoms of dysfunctions in social interactions and
communication skills, restricted interests, repetitive – stereotypic verbal and non-verbal
behaviors. Biomolecular evidence points to complex gene-environmental interactions in
ASDs. Several biochemical processes are associated with ASDs: oxidative stress (including
endoplasmic reticulum stress), decreased methylation capacity, limited production of glu-
tathione; mitochondrial dysfunction, intestinal dysbiosis, increased toxic metal burden, and
various immune abnormalities. The known immunological disorders include: T-lymphocyte
populations and function, gene expression changes in monocytes, several autoimmune-
related findings, high levels of N -acetylgalactosaminidase (which precludes macrophage
activation), and primary immune deficiencies. These immunological observations may
result in minicolumn structural changes in the brain, as well as, abnormal immune medi-
ation of synaptic functions. Equally, these immune dysregulations serve as the rationale
for immune-directed interventions such as hematopoietic stem cells (HSCs), which are
pivotal in controlling chronic inflammation and in the restoration of immunological balance.
These properties make them intriguing potential agents for ASD treatments.This prospec-
tive review will focus on the current state-of-the-art knowledge and challenges intrinsic in
the application of HSCs for ASD-related immunological disorders.
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AUTISM SPECTRUM DISORDERS: OVERVIEW
Autism and autism spectrum disorders (ASDs) are severe
heterogeneous neuro-developmental abnormalities character-
ized by dysfunctions in social interactions and communication
skills, restricted interests, repetitive, and stereotypic verbal and
non-verbal behaviors (American Psychiatric Association, 2000;
Stankovic et al., 2012). Autism related disorders are increasing
at an alarming rate and have now affected 2% (3.23% of boys) of
US school-aged children (Blumberg et al., 2013).
Autism spectrum disorders have multifactorial and polygenic
features which include: a complex combination of genetic, epi-
genetic, and environmental interactions (i.e., infectious agents,
air pollution, organophosphates, heavy metals) (Herbert, 2010;
Toro et al., 2010). An early inflammatory process has been pro-
posed as the potential etiology of ASDs (Depino, 2013). This
hypothesis is supported by animal models and has been exten-
sively reviewed by Meyer et al. (2009). Within that review, the
authors refer to the long-term consequences of prenatal immune
provocation in the rodent-model (Meyer et al., 2006). Specifi-
cally, experiments exposed pregnant mouse dames to PolyI:C (a
synthetic chemical resembling viral RNA) via tail vein infusion
at either mid or late gestation. Rapid induction of CNS cytokine
activity was noted in the pups which coincided with reduction
in reelin production. This effect was noted to have lifelong con-
sequences on both the structure and immune status of the CNS
in the mice following in utero exposure to a viral analog. Poten-
tially related to these animal models are the recent observations of
elevated N -acetylgalactosaminidase (Nagalase) levels in the blood
of children with ASDs (Bradstreet et al., 2012). This may reflect
ongoing viral latency, since Nagalase is observed to be elevated in
numerous viral-mediated acute and chronic disease states. This
latency may have been present from in utero or the early postnatal
period.
Others have observed minicolumn abnormalities in ASDs
(Casanova et al., 2006). As recently reviewed by Folsom and Fatemi
(2013), reelin is integrally involved in ASD pathophysiology and is
further a regulator of minicolumn structure and function. It there-
fore appears likely that in many ASDs an early (in utero or early
postnatal period) immunological insult disrupts reelin signaling
and cytokine communication in the CNS.
Still other biochemical and cellular processes are report-
edly associated with ASDs: oxidative stress, endoplasmic retic-
ulum stress, decreased methylation capacity, limited production
of glutathione, mitochondrial dysfunction, intestinal dysbiosis,
increased toxic metal burden, immune dysregulation, immune
activation of neuroglial cells (Siniscalco et al., 2012a). These
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findings may represent consequences of the primary etiological
processes. Regardless of the cause or effect nature of these observed
abnormalities, it is probably that these issues interfere with proper
CNS functioning in ASDs, and as such they are reasonable targets
for therapeutic interventions.
There is, however, a lack of consensus regarding the
etiopathologies of ASDs (Siniscalco et al., 2012a). Current med-
ication usage attempts to reduce the problematic behaviors,
without addressing the basic underlying etiologies (Chadman
et al., 2012; Hampson et al., 2012). These medications often
lack evidence of safety and efficacy for the core features of
ASD, and instead target maladaptive behaviors and comorbid
psychopathology (i.e., irritability, depression, anxiety, hyperac-
tivity, and obsessive-compulsive behaviors) (Siegel and Beaulieu,
2012).
Concerns over safety and limited availability of approved psy-
chotropic medications for children in general, has been encour-
aging the development of biomedical treatments to target specific
biological issues or symptoms. These include the use of: melatonin,
acetylcholinesterase inhibitors, naltrexone, carnitine, tetrahydro-
biopterin, vitamin C, glutamate antagonists, special dietary sup-
plements, hyperbaric oxygen treatment, immunomodulation and
anti-inflammatory treatments, oxytocin, acupuncture, music ther-
apy, and vision therapy (Filipek et al., 2006; Rossignol, 2009;
Bradstreet et al., 2010; Wong and Sun, 2010). Several behavioral
options are also currently used as effective intervention strat-
egy for autism (Kasari and Lawton, 2010; Vismara and Rogers,
2010).
In the midst of these various therapies, stem cell therapies are
emerging as the future of molecular and regenerative medicine
(Siniscalco et al., 2012b), and they are providing new opportu-
nities for ASD interventions (Siniscalco et al., 2012a; Siniscalco,
2013). Novel findings on the molecular and cellular basis of ASDs
indicate that at least some features of ASDs may be amenable to
stem cell therapy (Siniscalco, 2012).
AUTISM SPECTRUM DISORDERS: CNS INFLAMMATORY
CONDITIONS
One difficult feature of the immune dysregulation in ASDs appears
to be abnormal regulation of the blood brain barrier (BBB) (Theo-
harides and Zhang, 2011). The BBB functions are complex and
incompletely understood, however, it is clear that the BBB both
produces and regulates cytokines, and serves as an immunologi-
cal interface between the CNS and the peripheral immune system
(Siegel and Zalcman, 2008). Hematopoietic stem cells (HSCs) may
represent one of the few effective interventions to restore proper
regulation of the BBB in ASDs. Stem cells have been recently
proposed as elective candidate for modeling BBB (Lippmann
et al., 2013). A large number of endogenous HSCs was found in
brain (Bartlett, 1982). These HSCs provide constant generation of
macrophagic cells without the disturbance of BBB. Macrophagic
cells contribute to the normal homeostasis of brain function by
removing cellular debris, such as myelin fragments.
Exogenous transplanted stem cells are able to migrate into
CNS and retain the differentiation capacity (Simard and Rivest,
2004). Clearly, the BBB allows the passage of stem cells from
the blood into the brain or the spinal cord (de Munter and
Wolters, 2013), where they can exert their roles. Interestingly, it
has been demonstrated that stem cells, in vitro differentiated in
epithelial cells, possess many BBB-related attributes, such as well-
organized tight junctions, expression of nutrient transporters,
and polarized efflux transporter activity (Lippmann et al., 2012).
These properties are very useful in restoring BBB disruption. In
this way, in ASDs, transplanted stem cells could restore the BBB
characteristics.
Accumulating evidence points to a chronic up-regulation of
inflammatory cytokines in the ASD brain (Ginsberg et al., 2012;
Rose et al., 2012). Recently, a role of neuroinflammation and apop-
tosis mechanisms in the etiology of autism has been proposed
(El-Ansary and Al-Ayadhi, 2012), as several biochemical para-
meters related to inflammation were found up-regulated in chil-
dren with ASDs (El-Ansary and Al-Ayadhi, 2012; Siniscalco et al.,
2012c). Chronic peripheral and central alterations in the inflam-
matory response have been reported in ASDs (Depino, 2013).
Neuroinflammatory evidence was further documented by remark-
ably elevated levels of cerebrospinal fluid tumor necrosis factor-
alpha (TNF-α) in ASDs (Chez et al., 2007). TNF-α profoundly
inhibits synaptic communication (Zhang and Dougherty, 2011).
Correlations between pro-inflammatory cytokine levels and autis-
tic symptoms have been reported (Buehler, 2011). Interestingly,
the cerebellum and temporal cortex of autistic children show
decreased glutathione (GSH/GSSG) redox/anti-oxidant capacity
and increased oxidative stress associated to a chronic inflammatory
response (Rose et al., 2012). Glutathione is a critical intracellular
anti-oxidant and children with ASDs have documented deficien-
cies in the reduced form (James et al., 2006). Lowered GSH levels
indicate an adaptive response to ongoing inflammation or infec-
tion. In addition, it has been proposed that hyperbaric oxygen
therapy may mediate the noted benefits in ASDs via an anti-
inflammatory response, perhaps through mobilization of anti-
inflammatory CD34+ stem cells from the bone marrow (Rossignol
et al., 2012).
PRO-INFLAMMATORY INDICATIONS FROM BLOOD STUDIES
IN ASDs
At a molecular level, the transcriptional factor, nuclear factor-κB
(NF-κB) DNA binding activity was found elevated in peripheral
blood samples of children with autism (Naik et al., 2011). NF-κB
is an important gene involved in the mediation of inflamma-
tion and apoptosis, indicating that pro-inflammatory processes
in autism could be up-regulated by this transcriptional factor.
Increased NF-κB expression levels were found also in post-mortem
samples of orbito-frontal cortex from autistic patients, further
indicating a neuro-inflammatory condition (Young et al., 2011).
Peripheral blood mononuclear cells (PBMCs) demonstrate sig-
nificant aberrations in autistic children (Siniscalco et al., 2012c).
In autism, these cells are committed to a pro-inflammatory
state, via significantly more pro-inflammatory cytokines, includ-
ing TNFα and several interleukins, IL-1ßand IL-6. The ratio
of pro-inflammatory/anti-inflammatory cytokines, TNFα/tumor
necrosis factor receptor II (TNFR-II) was also higher in autistic
patients (Jyonouchi et al., 2001). The pro-inflammatory cytokine
IL-6 was found increased also in the cerebellum of autistic children
(Wei et al., 2011).
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GASTROINTESTINAL IMMUNE ALTERATIONS IN ASDs
In addition to the reported CNS immune issues in ASDs, the
intestinal tract (GI) has been studied as a source of chronic
inflammation in this population. Recently, extensive evaluation
of GI transcriptomes of a group of children with ASDs and
GI symptoms were compared to both health tissue, as well as
known cases of Crohn’s disease (CD) and ulcerative colitis (UC)
(Walker et al., 2013). Significant inflammatory transcriptome
overlap was observed between the ASD/GI group and both CD
and UC. However, the ASD/GI group demonstrated some dis-
tinctions in the inflammatory pattern. Various stem cell therapies
have been proposed for CD and UC, which may have appli-
cation to ASD/GI issues as well, but this is a complex issue.
One group recently demonstrated dysregulation of immune-
hematopoiesis in colitis mediated by inflammatory cytokines, with
increased proliferating HSCs in the bone marrow and spleen. They
further demonstrated increased granulocyte-monocyte progen-
itor (GMP) production at the expense of erythroid and lym-
phoid progenitors. GMPs were shown to exacerbate the colitis.
The Autologous Stem Cell Transplantation International Crohn’s
Disease (ASTIC) trial recently published the first round of data
(Hawkey, 2012). Bone marrow derived and expanded CD34+
stem cells were infused intravenously with some significant pos-
itive results (the Crohn’s Disease Activity Index (CDAI) fell
from 324 (median, interquartile range 229–411) to 161 (85–257,
n= 17).
HEMATOPOIETIC STEM CELLS AND THE INFLAMMATORY
STATE IN AUTISM
Hematopoietic stem cells take a pivotal role in controlling chronic
inflammation and in creating immune regulation, and are the
cells responsible for forming blood and immune cells. They were
found in circulating blood, the spleen, and bone marrow and are
characterized by specific cell markers belonging to the cluster of
differentiation family (CD34, CD59, CD90, and CD117). HSCs
show self-renewal, mobilization, and multipotent differentiation
capacities, as they are able to give rise to the myeloid (including
monocytes and macrophages) and lymphoid cells, replenishing
all blood cell types, and providing homeostasis of blood cells
(Sieburg et al., 2011). HSCs are also able to home to the damaged
sites (Kavanagh and Kalia, 2011). HSC transplantation has gained
much consideration as therapy for hematological malignancies
and for the treatment of severe autoimmune diseases (Muraro
and Uccelli, 2010).
Interestingly, it has been demonstrated that HSCs are strictly
connected with inflammation. Several inflammatory signaling
molecules are essential to the HSC response (Baldridge et al., 2011;
Boiko and Borghesi, 2012), indicating that the local microenviron-
ment plays an instructive role in stem cell fate (Smith and Calvi,
2013). While in normal condition HSCs travel through peripheral
blood at low number, they are strongly mobilized by inflam-
mation (Wright et al., 2001). The activation of inflammatory
cytokine signaling pathways promotes transcriptional changes
to drive immune and plasticity responses in HSCs (Baldridge
et al., 2011). Indeed, in inflammation processes, increased levels
of cytokines and hematopoietic growth factors trigger mobiliza-
tion and proliferation of HSCs, driving a quantitative in vivo
expansion of the hematopoietic tissue (Möhle and Kanz, 2007).
HSCs have demonstrated powerful effects also on acute inflam-
mation.
The ability of HSCs to traffic to sites of inflammation outside of
the bone marrow (Granick et al., 2012) suggests that they could be
a useful tool in treating inflammatory processes related to autism
pathology.
Pro-inflammatory molecules released in ASDs could be able
to recruit HSCs to the sites of major inflammation processes,
where these cells could exert their beneficial actions against
inflammation.
What are the exact molecular mechanism of action are still to
be fully elucidated. However, HSCs show paracrine ability (Rosen-
berg et al., 2012). As other stem cell subtypes, HSCs are able to
synthesize and release a broad variety of cytokines, chemokines,
and growth factors. These bioactive factors secreted from stem
cells suppress the altered immune responses, inhibit apoptosis and
stimulate recruitment, retention, mitosis, and differentiation of
tissue-residing stem cells (Zhou et al., 2009). Indeed, it has been
demonstrated that hematopoietic CD34(+) stem cells are able
to down-regulate the pro-inflammatory TNF-α, IFN-γ, and IL-
1, as well as to up-regulate the anti-inflammatory cytokine IL-10
(Greish et al., 2012) (Figure 1).
CHALLENGES IN THE APPLICATION OF HSCs TO ASDs
Although HSCs are attractive candidates for the restoration
of ASD-related immune-mediated pathologies, several concerns
must be addressed to adequately understand their proper appli-
cation. As mentioned previously, the BBB may not be properly
managing its immunological regulatory functions, and as such
it may allow abnormal trafficking of stem cells into the CNS
with resultant unintended consequences. Equally, HSCs may offer
desirable reparative functions to the BBB.
The reported structural and functional abnormalities of ASD
minicolumns present a daunting challenge to HSCs therapeutics.
However, progress with animal models should allow for ade-
quate testing of the amenability of minicolumnopathies to HSC
interventions.
In a recent review of the bidirectional nature of stem
cells to both repair and extinguish inflammatory processes, or
in contradistinction, to contribute to the maintenance of the
inflammatory state, the authors point out the importance of
proper cytokine signaling as deterministic of the end-effect of
stem cell responses (Shi et al., 2012). Others have expressed equal
concern over stem cell enhancement of inflammatory conditions
(Blanchet and McNagny, 2009; Siniscalco et al., 2011).
Thus, one feature of any effective HSC therapeutic applica-
tion must be consideration for proper cytokine signaling. In
particular, anti-inflammatory medications and potentially even
the anti-inflammatory effects of biological therapies, e.g., cur-
cumin or luteolin, may interfere with stem cell targeting and allow
them to exacerbate the existing inflammatory state. Again, the
hope is that animal modeling will assist in directing therapeutic
application.
In a similar way, the inflammatory bowel disease associated
with autism, may respond in a comparably favorable way to HSCs
as reported in the ASTIC trial. But once again caution must be
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FIGURE 1 | Possible mechanisms of action of hematopoietic stem cells
(HSCs) in autism spectrum disorder (ASD) therapy. Pro-inflammatory
molecules released in ASDs could recruit HSCs to the site of inflammation.
HSCs synthesize and release a broad variety of biofactors, including
cytokines, chemokines, and growth factors. These bioactive molecules
secreted from stem cells are able to suppress aberrant immune responses
and stimulate recruitment, retention, and activation of tissue-residing stem
cells. In addition, HSCs are able to down-regulate the pro-inflammatory TNF-α,
IFN-γ, and IL-1, that are responsible for neuroinflammatory processes in
ASDs, as well as to up-regulate the anti-inflammatory cytokine IL-10.
inserted as up-regulation of GMPs were noted in the autism pop-
ulation studied by Walker et al. (2013). A reasonable concern
would be the methodologies to prevent recruitment of HSCs to
this inflammatory GMP population.
Further complicating our application of HSCs to ASDs, relates
to the unresolved, underlying cause for the chronic inflammation.
It is reasonable to consider a chronic infectious agent(s) as the
maintainer of the immune dysregulations observed. Potentially,
the events leading to the inflammation may merely represent the
long-term consequences of an ill-timed exposure during gestation
or early postnatal life. The latter, would represent a more desirable
scenario for HSC therapeutics, while the former presents substan-
tial challenges. This also raises the issue of autologous or allogeneic
source material for the HSCs. While using autologous HSCs pre-
clude concerns over graft-versus-host reactions, these stem cells
may be programed by the latent infection is undesirable ways.
The severe risk of graft-versus-host disease (GVHD), the toxicity
of ablative conditioning, and the need for close donor-recipient
matching would need to be addressed if allogeneic sources of
HSCs were used (Leventhal et al., 2013). However, these serious
and life-threatening challenges make allogeneic HSCs undesirable
in ASDs.
SUMMARY
While HSCs are populations of multipotent stem cells that have
been identified as promising potential candidates for treating a
broad range of conditions; their basic biology remains inade-
quately characterized to answer all of the questions raised by their
use. Despite these concerns, HSCs, based on an internet review of
the stem cell providers offering services to patients, are already in
use for ASDs. As such, a better understanding of the HSC mol-
ecular mechanisms, as well as experimental or clinical data, is
urgently needed to provide more data to develop proper strate-
gies to improve the use of these cells in therapy in ASD in a large
scale (Kavanagh and Kalia, 2011).
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